Results 91 to 100 of about 5,674 (178)

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

, 2014
International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus ...
Linaberry, Misti, Yoffe, Boris, Peng, Cheng-Yuan, Hughes, Eric, Bronowicki, Jean-Pierre, Chu, Chi-Jen, Mcphee, Fiona, Sievert, William, Gerken, Guido, Noviello, Stephanie, Lee, Youn-Jae, Kao, Jia-Horng, Thabut, Dominique, Manns, Michael, Gordon, Stuart, Jacobson, Ira, Mendez, Patricia, Marcellin, Marc, Pol, Stanislas, Chang, Ting-Tsung, Métivier, Sophie, Everson, Gregory, Towner, William, Bourlière, Marc, Heo, Jeong, Kopit, Justin   +25 more
core   +1 more source

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection

, 2016
International audienceBACKGROUND & AIMS:We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients.METHODS:This phase
Buti, Maria, Ouwerkerk-Mahadevan, Sivi, Cheung, Kin, Bronowicki, Jean-Pierre, Loustaud-Ratti, Veronique, Beumont-Mauviel, Maria, Makara, Mihaly, Mcphee, Fiona, Hughes, Eric A., Pruitt, Ronald, Al-Assi, M. Tarek, Noviello, Stephanie, Gea, Francisco, Thabut, Dominique, Olveira, Antonio, Gadano, Adrian, Petersen, Joerg, Bifano, Marc, Bourliere, Marc, Picchio, Gaston, Boparai, Navdeep, Pol, Stanislas, Hezode, Christophe, Banyai, Tivadar, Zeuzem, Stefan   +24 more
core   +1 more source

Additional file 1: of Ionic liquid-based vortex-assisted DLLME followed by RP-LC-PDA method for bioassay of daclatasvir in rat serum: application to pharmacokinetics

, 2019
Figure S1. The schematic diagram showing the IL-DLLME process of daclatasvir from rat serum. Figure S2. The systematic predictable mechanism and its phase separation of IL from rat serum. Figure S3.
T. Rao (6648269), Marakada Sridevi (6648272), Challa Naidu (6648275), Bandaru Nagaraju (6648278)   +3 more
core   +1 more source

Daclatasvir: potential role in hepatitis C [Corrigendum] [PDF]

, 2014
Lee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor,
Lee C
core  

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND DACLATASVIR DRUG PRODUCT BY RP-HPLC METHOD

, 2017
Analytical method was developed for the estimation of Sofosbuvir and Daclatasvir drug substance by liquid chromatography. The chromatographic separation was achieved on C18 column (XTerra RP18 150*4.6, 5um) at ambient temperature .The separation achieved
Benzil Dudekula1*, Dr.C.Ramachandraiah2, Dr.N.Devanna3
core   +1 more source

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

, 2015
BACKGROUND & AIMS: Improved therapies for peginterferon/ribavirin null or partial responders are needed. This study evaluated daclatasvir (NS5A inhibitor) and asunaprevir (NS3 protease inhibitor) plus peginterferon alfa-2a and ribavirin in this ...
BRUNETTO, MAURIZIA ROSSANA, Everson, G, Kugelmas, M, Pol, S, Jensen, D., Vierling, J, Zeuzem, S, Serfaty, L, de Ledinghen, V, Elkhashab, M, Younes, Zh, Hézode, C, Hennicken, D, Bernstein, D, Sherman, Ke, Luketic, V, Mauss, S, Heo, J, Mcphee, F, Tran, A   +19 more
core   +1 more source

Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15)

, 2018
BACKGROUND: Antiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. AIMS: To examine the virological response and effect of viral clearance in patients with decompensated hepatitis C ...
Angus, PW, Mason, S, Strasser, SI, McCaughan, GW, Thwaites, PA, Mitchell, J, Morales, B, George, J, Jeffrey, G, Gow, P, Tallis, C, Roberts, SK, Thompson, AJ, Wigg, A, Parker, FC   +14 more
core   +1 more source

Uso del Sofosbuvir y Daclatasvir en el tratamiento de pacientes con hepatitis C / Use of Sofosbuvir and Daclatasvir in the treatment of patients with hepatitis C [PDF]

Introducción: La Infección por el virus de la hepatitis C constituye un problema sanitario a nivel mundial por su elevada incidencia. El tratamiento para esta infección experimentó un cambio en los últimos años con la comercialización de los Antivirales ...
Muñoz Castañeda, Misael Bárbaro, Díaz Elías, Javier Orlando, Fernández Sotolongo, José, Pardías Izaguirre, Yaimara, Ortiz Montero, Yosvani Josué, Arús Soler, Enrique Rogelio   +5 more
core  

Increasing competition in pharmaceutical tenders: Patents, treatment guidelines, and centralised procurement of Hepatitis C drugs in Brazil. [PDF]

Glob Public Health
Mercadante E.
europepmc   +1 more source

Unravelling HCV diversity and resistance in Viet Nam: a cross-sectional analysis. [PDF]

Lancet Reg Health West Pac
Le Ngoc C, Chai H, Airey G, Das T, Jennings D, Xu F, Flower B, Marjaneh MM, McCabe L, Le Manh H, Nguyen Van Vinh C, Trong TD, Ngoc TP, Thi Thu HV, Thwaites GE, van Doorn HR, Day J, Kestelyn E, Le Van T, Rahman M, Pett S, Barnes E, Walker AS, Cooke GS, Ansari MA.   +24 more
europepmc   +1 more source